Palatin Technologies plans to start clinical trials of its ulcerative colitis therapy PL-8177 in the next three months. The U.S. Food and Drug Administration’s decision to accept Palatin’s Investigational New Drug application for the treatment ... Read more

Seres Therapeutics has secured an orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for SER-287, its therapy to treat ulcerative colitis in children. ODD offers companies ... Read more

Seres Therapeutics, Inc., announced the initiation of two academic research collaborations to further develop the company’s microbiome therapeutics platform as a treatment for inflammatory bowel disease (IBD). Under the agreements, ... Read more

Seres Therapeutics, Inc., a company focused on the development of drugs targeting the unhealthy microbiome for the treatment of inflammatory, metabolic and infectious diseases, recently announced the initiation of ... Read more

Disclaimer:

IBD News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Pin It on Pinterest

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more